McClure Erin A, Rabin Rachel A, Lee Dustin C, Hindocha Chandni
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Curr Addict Rep. 2020 Dec;7(4):533-544. doi: 10.1007/s40429-020-00334-8. Epub 2020 Oct 2.
The goal of this article is to summarize the treatment-focused literature on cannabis and tobacco co-use and the treatment implications of co-use. This review will focus on: 1) the impact of co-use on cessation outcomes, 2) compensatory use/substitution of the non-treated substance among co-users, and 3) treatment interventions to address co-use. This article will highlight the limitations to co-use captured in the literature and offer considerations and directives for co-use research and treatment moving forward.
The degree to which co-use affects cessation for a single, targeted substance remains in question, as the literature is largely mixed. Cannabis treatment trials are better equipped to answer these questions given that they do not typically exclude tobacco users. While the relationship between tobacco use and poorer cannabis outcomes appears to have some evidence, the reverse relationship (cannabis use affecting tobacco outcomes) is not consistently supported.
The co-use of cannabis and tobacco and its impact on single substance cessation and/or compensatory substance use during cessation is generally overlooked in treatment trials, while interventions to address both substances are rare. Capturing co-use adds burden for researchers, clinicians, and participants, but is warranted given the prevalence of co-use and a rapidly changing cannabis and tobacco regulatory environment, which may further complicate co-occurring substance use. Co-users are a heterogeneous population; trials focused on co-users, in addition to better data capture and consistent terminology, will aid in an understanding of nuanced patterns of co-use critical to inform treatment interventions.
本文旨在总结以大麻与烟草共同使用及共同使用对治疗的影响为重点的文献。本综述将聚焦于:1)共同使用对戒烟结果的影响;2)共同使用者中未治疗物质的代偿性使用/替代;3)针对共同使用的治疗干预措施。本文将强调文献中关于共同使用的局限性,并为未来的共同使用研究和治疗提供考虑因素和指导方针。
由于文献结果大多参差不齐,共同使用对单一目标物质戒烟的影响程度仍存在疑问。鉴于大麻治疗试验通常不排除烟草使用者,因此更有能力回答这些问题。虽然烟草使用与较差的大麻使用结果之间的关系似乎有一些证据支持,但相反的关系(大麻使用影响烟草使用结果)并未得到一致支持。
在治疗试验中,大麻和烟草的共同使用及其对单一物质戒烟和/或戒烟期间代偿性物质使用的影响通常被忽视,而针对这两种物质的干预措施很少见。记录共同使用情况给研究人员、临床医生和参与者增加了负担,但鉴于共同使用的普遍性以及大麻和烟草监管环境的迅速变化,这是必要的,因为这可能会使同时出现的物质使用情况更加复杂。共同使用者是一个异质性群体;除了更好的数据记录和一致的术语外,针对共同使用者的试验将有助于理解对指导治疗干预至关重要的细微共同使用模式。